期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 21, 期 4, 页码 237-251出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2010.04.002
关键词
Interferon-lambda; Soluble receptor cancer; Cytokine receptor family class 2; Therapy
资金
- Deutsche Forschungsgemeinschaft (German Research Foundation) [WO 1567/1-1]
IL-28A, IL-28B and IL-29 (also designated type III interferons) constitute a new subfamily within the IL-10-interferon family. They are produced by virtually any nucleated cell type, particularly dendritic cells, following viral infection or activation with bacterial components, and mediate their effects via the IL-28R1/IL-10R2 receptor complex. Although IL-28/IL-29 are closer to the IL-10-related cytokines in terms of gene structure, protein structure, and receptor usage, they display type I interferon-like anti-viral and cytostatic activities. Unlike type I interferons, the target cell populations of IL-28/IL-29 are restricted and mainly include epithelial cells and hepatocytes. These properties suggest that IL-28/IL-29 are potential therapeutic alternatives to type I interferons in terms of viral infections and tumors. This review describes the current knowledge about these cytokines. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据